<DOC>
	<DOCNO>NCT01657162</DOCNO>
	<brief_summary>The purpose study provide 24 month standard care data subject previously enrol study BA058-05-003 .</brief_summary>
	<brief_title>Twenty Four Month Extension Study BA058-05-003</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>1 . The subject enrol , randomize either BA058 ( abaloparatide ) placebo arm , successfully complete Study BA05805003 . 1 . Were withdrawn Study BA05805003 reason . 2 . Experienced treatmentrelated SAE Study BA05805003 .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>BA058</keyword>
	<keyword>Abaloparatide-SC</keyword>
	<keyword>abaloparatide</keyword>
	<keyword>ACTIVExtend</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>fracture</keyword>
	<keyword>bone loss</keyword>
</DOC>